REG - Cizzle Biotechnology - Further Research Agreement with University of York

Cizzle Biotechnology HoldingsAnnouncement

11/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220411:nRSK8728Ha&default-theme=true

RNS Number : 8728H  Cizzle Biotechnology Holdings PLC  11 April 2022

11 April 2022

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

 

Further Research Agreement with the University of York for Cancer Diagnosis
and Therapy

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to
announce that it has entered into a further research agreement with the
University of York for the development of potential applications in cancer
diagnosis and therapy. This includes the evaluation of the Company's
proprietary biomarker for detecting a multiple range of cancers in addition to
the existing programme for early lung cancer detection.

 

Highlights

 

·    New 12-month research and development agreement with the University
of York

·    All intellectual property rights arising from the work to be owned by
the Company

·    Strengthens the Company's position in creating new solutions for
early cancer diagnostics and therapeutic tools

·    Extends access to expert resource and capability for developing the
Company's early detection tests for lung cancer and potentially other forms of
cancer

 

This new agreement, to commence for a period of 12 months from 25 June 2022,
follows the successful programme announced on 17 September 2021 for the
development and validation of molecular tools with potential application in
cancer diagnosis or therapy, and their configuration into assays for Cizzle
Biotechnology's proprietary cancer biomarker variants. Cizzle Biotechnology
will own all intellectual property rights arising from the work which
strengthens the Company's position in creating new solutions for early cancer
diagnostics and therapeutic tools.

 

Cizzle Biotechnology's origins were as a spin out from the University of York
based on research and development by Professor Dawn Coverley at the
University. This new agreement builds on the continuing long-term
collaboration between Cizzle Biotechnology and the University of York,
providing access to leading edge research facilities and expertise.

 

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "The
challenge of developing breakthrough early-stage diagnostic tests and
therapies for cancer is extraordinary and working closely with one of the
world's premier research-intensive institutions greatly facilitates Cizzle
Biotechnology's ambitions to provide simple, rapid tests that can detect
cancer early when curative surgical intervention is possible. This new
agreement extends our access to expert resource and capability for developing
our early detection tests for lung cancer and potentially other forms of
cancer."

Enquiries:

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCILMMTMTMMBAT